Egyptian International Pharmaceutical Investments (CAI:PHAR) Other Operating Expense : E£655 Mil (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Other Operating Expense?

Egyptian International Pharmaceutical Investments's Other Operating Expense for the three months ended in Dec. 2023 was E£150 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was E£655 Mil.

Egyptian International Pharmaceutical Investments's quarterly Other Operating Expense declined from Jun. 2023 (E£192 Mil) to Sep. 2023 (E£164 Mil) and declined from Sep. 2023 (E£164 Mil) to Dec. 2023 (E£150 Mil).

Egyptian International Pharmaceutical Investments's annual Other Operating Expense increased from Dec. 2021 (E£443 Mil) to Dec. 2022 (E£568 Mil) and increased from Dec. 2022 (E£568 Mil) to Dec. 2023 (E£655 Mil).

Egyptian International Pharmaceutical Investments Other Operating Expense Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Other Operating Expense Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

1,251.54

1,211.13

443.15

567.88

655.04

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Operating Expense	Get a 7-Day Free Trial															153.81	148.54	191.90	164.13	150.47

Egyptian International Pharmaceutical Investments Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£655 Mil.

Egyptian International Pharmaceutical Investments Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.